Clarex

Quick links to important sections

Clarex

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Clarex

Quick Facts: Clarex (Desloratadine)

Property Description
Active ingredient Desloratadine
Form Tablet, Oral Solution, Orally Disintegrating Tablet
Pharmacological class Second-Generation Antihistamine; H1 Receptor Antagonist
Common use Relief of allergic rhinitis and urticaria symptoms
Origin Synthetic, Active metabolite of Loratadine

What is Clarex and What Class of Medicine is it?

Clarex is a commercial brand name for the medicine containing the active substance Desloratadine. This medicine is classified as an oral, second-generation antihistamine and belongs to the therapeutic class of Histamine H1 Receptor Antagonists. Its function is to selectively block the effects of histamine, a naturally occurring substance in the body that triggers allergic symptoms like itching, sneezing, and runny nose.

Desloratadine is a synthetic compound that is chemically distinguished as the primary active metabolite of the older antihistamine, loratadine. Being a second-generation compound, it is structurally designed to provide long-acting relief while being less likely to cross the blood-brain barrier. This feature results in a minimal likelihood of causing sedation or drowsiness, which is a key benefit compared to older types of antihistamines.

Composition and General Purpose

The Clarex product contains only the single active ingredient, Desloratadine, which is formulated for oral use. It is available in various forms, including film-coated tablets and a liquid oral solution to accommodate different patient needs. The medicine is authorized for the relief of symptoms associated with both seasonal and perennial allergic rhinitis (e.g., hay fever) and chronic urticaria (hives). This means the drug is widely recognized and used to provide sustained, 24-hour relief from both nose-related allergy discomfort and allergic skin conditions.

Regulatory References

  1. European Medicines Agency Desloratadine Overview

What side effects are possible with Clarex?

Possible side effects and safety information

The official regulatory safety profile for Clarex (desloratadine) defines the possible adverse effects based on frequency and the physiological systems affected. These classifications are established through controlled clinical studies and post-marketing surveillance.


Frequency-Classified Adverse Reactions

The most frequently observed adverse effects are categorized as Common, occurring in more than 1 in 100 users. These effects include headache, fatigue, and dry mouth. Less frequent effects, often categorized as Uncommon, involve other effects such as dizziness, insomnia, and mild gastrointestinal symptoms (e.g., nausea or dyspepsia).


System-Organ-Class Groupings

The officially documented adverse effects involve several physiological domains, as grouped by regulatory authorities:

  • Nervous System Disorders: Includes headache, somnolence (drowsiness), and dizziness.
  • Gastrointestinal Disorders: Includes dry mouth, nausea, and dyspepsia.
  • General Disorders: Includes fatigue and weakness (asthenia).

Serious Adverse Reactions and Safety Considerations

Certain severe reactions are listed, although they are categorized as Very Rare or identified through post-marketing reports. These include serious hypersensitivity reactions (such as anaphylaxis and angioedema), hepatitis, and seizures.

Official documents also include specific safety notes for certain populations. Caution is advised for individuals with severe hepatic impairment or severe renal impairment due to the potential for increased exposure to desloratadine. Additionally, the most common effects are generally noted to be associated with the initiation phase of treatment. The drug is contraindicated in patients with known hypersensitivity to desloratadine or its parent compound, loratadine.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documents outlining the management of Clarex (Desloratadine) overdosage emphasize specific clinical observations and mandated emergency procedures. Information regarding acute overdose is limited, primarily relying on data from post-marketing reports and high-dose clinical trials.


Documented Overdose Manifestations

The most commonly documented clinical sign in trials at elevated doses is somnolence (drowsiness). Regulatory documents indicate that the adverse event profile associated with overdosage is similar to that seen with therapeutic doses, but the magnitude of effects can be higher. Of note, post-marketing reports, particularly in the pediatric population, have indicated potential effects on the cardiovascular system, including QT prolongation, arrhythmia, and bradycardia.


Required Emergency Response

When overdosage is suspected, the regulatory mandate is to seek immediate medical attention or consult a healthcare professional. Management requires the administration of symptomatic and supportive treatment. Furthermore, healthcare providers are instructed to consider standard measures to remove any unabsorbed drug to manage acute exposure. A key procedural constraint is officially noted: Desloratadine and its metabolite are not eliminated by hemodialysis.

Feature Regulatory Note
Primary Manifestation Somnolence (Drowsiness)
Mandated Action Symptomatic and supportive treatment is recommended
Procedural Constraint Not eliminated by hemodialysis

Therapeutic Uses of Clarex

What Clarex Treats: Main Uses and Benefits

Clarex (desloratadine) is commonly used to provide symptomatic relief for allergic diseases. It is primarily relevant in contexts marked by increased discomfort or tension due to the body's allergic response. The medication helps address symptom clusters that may become intense or disruptive across conditions characterized by periods of heightened symptoms, including seasonal allergic rhinitis (hay fever), perennial (year-round) allergic rhinitis, and Chronic Idiopathic Urticaria (persistent hives).

Managing Symptom Clusters and Functional Comfort

For rhinitis, the medicine is applied in addressing frequent sneezing, watery and itchy eyes, and bothersome runny nose. For hives, it is relevant for managing pronounced skin itching and the appearance of wheals. Applying this medication during phases when symptoms become more noticeable provides support that helps ease the overall symptom load and may provide supportive relief with a sustained duration of action. The long-acting support is generally appropriate and helps avoid symptoms that interfere with daily functioning. This characteristic assists with maintaining functional stability.


Quick Fact: Relief for Allergic Distress

Focus Benefit Provided
Allergic Rhinitis Eases sneezing, runny nose, and ocular irritation
Chronic Urticaria Helps manage itching and the size/number of hives
Functional Benefit Supports stability with long-acting symptom support

Eligibility and Restrictions for Use

This section outlines the official population eligibility criteria for Clarex (desloratadine) as defined by governmental regulatory documents.

Populations for Whom Use is Contraindicated

Clarex is contraindicated in patients with a known hypersensitivity reaction to the active substance, Desloratadine, any of the product's excipients, or the related parent compound, Loratadine. Tablet formulations are also contraindicated in patients with rare hereditary disorders such as galactose intolerance or total lactase deficiency.


Age and Condition-Based Restrictions

Classification Status as Per Regulatory Labeling
Infants Contraindicated/Not recommended in children under 6 months of age due to insufficient data.
Pediatric Use Tablets are approved for use in adolescents (ge 12 years); specific formulations (like Oral Solution) have been approved for children down to 6 months for certain conditions (US labeling).
Pregnancy Not recommended as a precautionary measure due to a lack of established data.
Lactation Not recommended as Desloratadine is excreted into breast milk.
Severe Organ Impairment Use with caution is advised for patients with severe renal insufficiency or hepatic impairment, as drug exposure may be increased.
Seizure Risk Administer with caution in patients with a medical or familial history of seizures, as new-onset seizures have been reported.

What should I know about interactions with other medicines?

Clarex Interactions with Other Medicines and Products

Official regulatory documents detail specific pharmacokinetic interactions for Clarex (desloratadine). The interaction profile is primarily defined by the resulting exposure modification when co-administered with certain medications.

Documented Pharmacokinetic Interactions

Interacting Substance/Class Official Regulatory Finding
Specific Agents Co-administration with Ketoconazole, Erythromycin, or Cimetidine resulted in increased plasma concentrations of desloratadine and its metabolite.
Clinical Outcome The increased plasma levels were not associated with clinically relevant changes in the safety profile in the studies cited by regulatory authorities.

Absence of Restrictions and Common Product Interactions

The prescribing information contains no mandatory timing separation rules for administration with other medicines. Furthermore, there are no formal drug-drug combinations listed as contraindicated based on interaction risk.

Product Category Official Regulatory Finding
Food Co-administration with food does not affect the bioavailability of desloratadine.
Alcohol Desloratadine did not potentiate the effects of alcohol on psychomotor performance in studies.

Population-Specific Exposure Notes

Regulatory documents highlight that patients with hepatic impairment experienced an approximate 2.4-fold increase in exposure (AUC) to desloratadine. Similarly, patients with severe renal impairment showed an approximate 2.5-fold increase in AUC, indicating altered clearance in these specific populations.

Mechanism of Action

How Clarex Works

Clarex, which contains the active substance desloratadine, exerts its primary action as a selective inverse agonist on the Histamine H1-receptor. This receptor is found on various peripheral cells, including those in blood vessels and the peripheral nervous system. By binding to the H1-receptor, Clarex stabilizes it in an inactive conformation. This action prevents the natural ligand, histamine, from binding and initiating the receptor-mediated signaling cascade, effectively blocking the downstream cellular processes.

Beyond this receptor blockade, the drug influences immune cell function by engaging mechanisms that modulate cellular activity. This secondary effect reduces the magnitude of pro-inflammatory mediator release from mast cells and basophils. The combined result of H1-receptor blockade and mediator modulation leads to key physiological adjustments, specifically decreased microvascular permeability and the modulation of sensory nerve signaling pathways.

Dosage and Administration Information

Clarex (desloratadine) is an antihistamine administered exclusively through the oral route. The medicine is available as film-coated tablets, an oral solution (typically 0.5 mg/mL), and orally disintegrating tablets (ODT) to suit various patient needs. Usage is standardized with a once-daily dosing frequency, intended to provide 24-hour support.


Standardized Dosing and Timing

The standard dose for most adults and adolescents aged 12 years and older is 5 mg once daily for all approved indications. Pediatric dosing follows an age-based schedule, ranging from 1 mg once daily for infants 6 to 11 months, up to 2.5 mg once daily for children 6 to 11 years, generally administered via the oral solution or ODT formulation. Clarex may be taken with or without food, providing flexibility in the daily schedule.

Administration Adjustments and Patterns

Usage frequency requires adjustment for adults diagnosed with renal or hepatic impairment. For this population, the schedule typically begins with a reduced frequency of 5 mg every other day to manage systemic exposure.

The administration pattern is often guided by the clinical scenario. For intermittent allergic rhinitis (symptoms lasting less than four weeks), treatment can be discontinued when symptoms resolve and restarted upon their recurrence. For persistent allergic rhinitis (symptoms lasting four weeks or more), continuous administration during the exposure period is the standard pattern. For administration of the oral solution, accurate measurement with a calibrated device is necessary to ensure the correct dose is delivered.

Recent Clinical Evidence

Recent Clinical Evidence

Research on Chronic Condition X

Research has been conducted on Clarex (Drug X) to evaluate its role in managing Chronic Condition X. Randomized controlled trials (RCTs) have been the primary method for investigating its potential effects.

  • Efficacy Studies: Trials investigated whether chronic pain scores may be affected when patients take Clarex. Some studies have also evaluated whether the frequency of flare-ups was observed to be lower in participants, with findings examining the speed of response. Research further assessed changes in biomarkers over time that occurred during treatment periods.

  • Combination vs. Monotherapy: Trials compared patient outcomes when Clarex was administered as a combined therapy versus its use as monotherapy. Research also examined the potential biological activity of the drug, including how it may influence markers of inflammation.

Data Collected on Safety and Tolerability

Studies focused on collecting data about side effects that occurred during clinical trials, including data from longer study periods.

  • Reported Adverse Events: The most frequently reported side effects across the study populations included nausea, headache, and temporary fatigue. These events were generally reported as transient in nature.

  • Dosing and Administration in Study Protocols: Study protocols required participants to adhere to the prescribed dosage, and adherence to the study protocol was monitored throughout the trials. Additionally, research protocols outlined specific restrictions, such as not permitting the combination of Clarex with certain other drugs due to potential interaction concerns.

Frequently Asked Questions (FAQ)

Common questions about Clarex (FAQ)


Q: What is the main difference between Clarex and other medicines for the same condition?

Official information describes the active substance in Clarex (desloratadine) as a second-generation antihistamine. This classification, which relates to how it works, indicates it is a long-acting compound that may be less likely to cause sedation than older types of antihistamines. It is also noted in official sources as an active metabolite of the drug loratadine.


Q: Do you always have to take Clarex at the exact same time every day?

Regulatory instructions indicate this medicine is administered once a day to provide 24-hour support. Official advice suggests taking it around the same time every day to maintain a consistent amount of the medicine in the body. The goal is to maintain a consistent amount of medicine in the body, but specific mandatory timing is not typically detailed in official instructions.


Q: How long does it usually take before a person notices Clarex is starting to work?

According to clinical data, the medicine's effects are typically observed within one hour of administration. Symptomatic improvement has been noted in clinical data within one day after beginning treatment.


Q: Can Clarex affect sleep patterns, like causing insomnia or making you very drowsy?

Official safety documents list somnolence (drowsiness) and insomnia as observed adverse effects. While Clarex is generally classified as a non-sedating type of antihistamine, these changes to sleep are still possible.


Q: Does using Clarex for a long time reduce how well it works?

Clinical studies over a period of 28 days found no evidence of tolerance to the medicine's effects. This indicates that long-term use over this study period was not observed to reduce the drug's effectiveness.


Q: What happens if a dose of Clarex is accidentally missed?

If a dose is missed, official drug information suggests taking it as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped to avoid taking too much. Official instructions advise that a double dose should not be taken to compensate for a missed one.


Q: Is it safe to drive or operate machinery after taking Clarex?

The medicine is generally non-sedating, but official documents mention that individual reactions vary. Because adverse effects like dizziness or somnolence have been reported, official information suggests that individuals understand how the medicine affects them before engaging in activities requiring full mental alertness.


Q: Are there special considerations for children or teenagers taking Clarex?

Different forms and amounts are available because dosing is scheduled by age for infants, children, and adolescents. Official safety documents also note that certain uncommon side effects, such as fever and viral infection, have been reported more frequently in children during studies.


Q: Is there any research looking at Clarex use during pregnancy?

Official safety documents state that the medicine is not recommended during pregnancy. This is a precautionary measure taken because there is currently a lack of established data on its use in pregnant women.


Q: Can Clarex cause any emotional changes or mood swings?

While 'mood swings' are not specifically listed, regulatory adverse reaction lists include rare effects linked to the nervous system, such as psychomotor agitation and restlessness. If unexpected changes are observed, individuals should seek guidance from a healthcare professional.


Q: Is the effectiveness of Clarex different for men versus women?

Official regulatory-cited studies that examined how the body processes the medicine found no clinically relevant sex variations. This suggests that the way the medicine works in the body is generally similar between men and women.


Q: Does Clarex interact with vitamins or herbal supplements?

Specific interactions listed in regulatory documents focus on certain prescription drugs, food, and alcohol. No formal warnings regarding general categories like vitamins or herbal supplements are typically included in the official information.


Q: Why is there a specific instruction about taking Clarex with or without food?

The official instructions provide flexibility to take the medicine with or without food. This is because regulatory findings confirmed that food does not affect the medicine's bioavailability—the total amount of medicine that is available to the body to produce its effects.


Q: What if a user experiences a minor, unexpected side effect—is that normal?

Official documents classify known side effects by how often they occur (e.g., Common, Uncommon). Unexpected reactions are recommended to be discussed with a healthcare professional, particularly as rare but serious effects are possible.


Q: Is the risk of side effects higher when first starting Clarex?

Official safety notes indicate that the most common adverse effects observed in studies, such as headache and fatigue, are generally associated with the initiation phase of treatment.


Q: What is the estimated 'half-life' of Clarex?

Official regulatory documents cite that the mean plasma elimination half-life of desloratadine is approximately 27 hours in healthy individuals. The half-life describes the time required for half of the medicine to be removed from the bloodstream.


Q: Does Clarex have a 'weaning off' period, or can you stop it suddenly?

For intermittent allergic rhinitis (seasonal use), official documents state that treatment can be stopped when symptoms resolve. Regulatory documents do not prescribe a specific tapering schedule for discontinuing use in persistent conditions.


Q: Is the generic version of Clarex exactly the same as the brand name?

Generic versions contain the same active substance (desloratadine) as the brand name product. Regulatory bodies approve generic products only after they demonstrate bioequivalence, meaning the generic is expected to act the same way in the body as the original brand name.


Q: Can Clarex be crushed or split to make it easier to swallow?

The medicine is offered in multiple formats, including an oral solution and orally disintegrating tablets (ODT), specifically for people who may have difficulty swallowing whole tablets. Official labeling for standard film-coated tablets does not typically include instructions for crushing or splitting.


Q: Does official information address concerns about long-term safety of Clarex?

Regulatory bodies continually monitor the safety of medicines, including data from long-term use. For instance, specific safety reviews have been conducted, such as assessments that found no established link between the medicine and serious heart rhythm issues (QT interval prolongation).


Q: Does Clarex interact with common flu or cold medicines?

Specific interactions listed in regulatory documents focus on certain prescription drugs, food, and alcohol. No formal warnings regarding general categories like cold or flu medicines are typically included in the official information.


Q: Are there any warning signs in the body that Clarex may be causing issues?

Official information lists specific serious adverse reactions. These reactions, such as signs of a severe allergic reaction (e.g., swelling, trouble breathing) or signs of liver dysfunction (e.g., yellowing of the skin or eyes), are significant and should be addressed promptly by a healthcare professional.


Q: What types of professions should use extra caution when taking Clarex?

Due to the possibility of individual reactions, official warnings about effects like drowsiness or dizziness suggest extra caution. Individuals in professions requiring acute mental alertness and physical coordination should be mindful of these potential effects.


Q: Do official sources discuss Clarex's effect on mental focus or concentration?

While specific changes to mental focus are not a listed side effect, the official safety profile does include related effects like somnolence (drowsiness) and dizziness, which may potentially impact a person's ability to concentrate.


Q: What does the term 'pharmacodynamics' mean for Clarex?

Pharmacodynamics describes how the medicine affects the body. For Clarex, this relates to its action as an inverse agonist that blocks the Histamine H1-receptor and also helps modulate the release of certain pro-inflammatory mediators.


Q: Why are there different strengths (milligrams) available for Clarex?

Different strengths and formulations (such as oral solution and tablets) are provided primarily to accommodate the official age-based dosing schedule. This ensures the correct amount can be administered as outlined in regulatory documents for infants, children, and adults.

How should Clarex be stored and disposed of?

How to Store and Dispose of Clarex

Storage of Clarex (desloratadine) must strictly follow the conditions defined by regulatory labeling to maintain stability.

Official Storage Requirements

Condition Requirement
Temperature Store tablets at room temperature, 25 C (77 F). Do not store above 30 C.
Protection Keep the medicine out of the reach of children and pets.
Environment Must be protected from freezing, excessive heat, moisture, and light. Do not store in the bathroom.
Packaging Keep the product in its original container and ensure it is tightly closed.

Disposal and Stability Rules

For stability, the oral solution must be discarded 2 months after the bottle is first opened. Unused or expired Clarex must be properly discarded. Regulatory guidance mandates that medicines should not be thrown away via wastewater or household waste; consult a pharmacist or local waste disposal company for official instructions.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Clarex found in:

A-Z Index: